Literature DB >> 10228108

Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection.

H L Twigg1, D M Soliman, R B Day, K S Knox, R J Anderson, D S Wilkes, C T Schnizlein-Bick.   

Abstract

Lymphocytic alveolitis portends a poor prognosis in human immunodeficiency virus (HIV)-infected subjects. Because alveolar lymphocytes consist predominantly of HIV-specific CD8(+) cytotoxic T lymphocytes (CTL), they could represent an appropriate immune response to infected cells in the lung, and be a surrogate marker for a high pulmonary viral burden. We assessed long-term outcome in a cohort of asymptomatic HIV-infected subjects who underwent bronchoscopy between 1990 and 1993 and had bronchoalveolar lavage fluid (BALF) available for determination of viral load by reverse transcription-polymerase chain reaction. The ability to detect HIV in BALF increased with disease progression. Lymphocytic alveolitis, although present at all stages of HIV infection, was most pronounced in patients with middle stage disease. The HIV viral load as measured by bronchoalveolar lavage correlated with the percentage of alveolar lymphocytes in patients with peripheral blood CD4(+) cell counts above 200/microliter. Including patients with CD4(+) cell counts < 200/microliter weakened this correlation, possibly because of replacement of CD8(+) CTL by CD8(+) suppressor cells in advanced disease. Free virus in BALF was a stronger predictor of HIV disease progression than was lymphocytic alveolitis. These data suggest that lymphocytic alveolitis in HIV-infected subjects occurs in response to viral antigens in the lung and that the poor prognosis associated with lymphocytic alveolitis reflects a high pulmonary viral burden.

Entities:  

Mesh:

Year:  1999        PMID: 10228108     DOI: 10.1164/ajrccm.159.5.9808031

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  50 in total

1.  Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy.

Authors:  Kenneth S Knox; Carol Vinton; Chadi A Hage; Lisa M Kohli; Homer L Twigg; Nichole R Klatt; Beth Zwickl; Jeffrey Waltz; Mitchell Goldman; Daniel C Douek; Jason M Brenchley
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

2.  HIV antiretroviral therapy reduces circulating surfactant protein-D levels.

Authors:  K M Kunisaki; H Quick; J V Baker
Journal:  HIV Med       Date:  2011-10       Impact factor: 3.180

Review 3.  The immunocompromised host: HIV infection.

Authors:  James M Beck
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Incidence of chronic obstructive pulmonary disease in people with HIV in Ontario, 1996-2015: a retrospective population-based cohort study.

Authors:  Tony Antoniou; Zhan Yao; Janet Raboud; Andrea S Gershon
Journal:  CMAJ Open       Date:  2020-02-18

Review 5.  Mechanisms Underlying HIV-Associated Noninfectious Lung Disease.

Authors:  Rachel M Presti; Sonia C Flores; Brent E Palmer; Jeffrey J Atkinson; Catherine R Lesko; Bryan Lau; Andrew P Fontenot; Jesse Roman; John F McDyer; Homer L Twigg
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

6.  Measurement of antiretroviral drugs in the lungs of HIV-infected patients.

Authors:  Homer L Twigg; Carol T Schnizlein-Bick; Michael Weiden; Fred Valentine; Joseph Wheat; Richard B Day; Helen Rominger; Lu Zheng; Ronald G Collman; Robert W Coombs; R Pat Bucy; Naser L Rezk; Angela Dm Kashuba
Journal:  HIV Ther       Date:  2010-03-01

7.  Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.

Authors:  Jason M Brenchley; Mirko Paiardini; Kenneth S Knox; Ava I Asher; Barbara Cervasi; Tedi E Asher; Phillip Scheinberg; David A Price; Chadi A Hage; Lisa M Kholi; Alexander Khoruts; Ian Frank; James Else; Timothy Schacker; Guido Silvestri; Daniel C Douek
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

Review 8.  Obstructive Lung Diseases in HIV: A Clinical Review and Identification of Key Future Research Needs.

Authors:  M Bradley Drummond; Ken M Kunisaki; Laurence Huang
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

Review 9.  Lung Malignancies in HIV Infection.

Authors:  Keith Sigel; Robert Pitts; Kristina Crothers
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

Review 10.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.